Buscar resultados de ensayos clínicos
Osteosarcoma - 28 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Development of Indices Predicting Response to Pre-operative Chemotherapy in Osteosarcoma Patients Condición: Osteosarcoma Fecha: 2008-05-27 |
Not yet recruiting |
Nombre del estudio: Therapy Trial to Determine the Safety and Efficacy of Heavy Ion Radiotherapy in Patients With Osteosarcoma Condición: Osteosarcoma Fecha: 2009-10-23 Intervenciones: Radiation: heavy ion radiotherapy (C12) Desired target of |
Completed |
Nombre del estudio: Chemotherapy for Patients With Osteosarcoma Condición: Osteosarcoma Fecha: 2007-08-29 Intervenciones: Drug: Pemetrexed 500 mg/m^2, IV every 21 days until disease progression, unacceptable toxicity, particip |
Active, not recruiting |
Nombre del estudio: A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung Condición: Osteosarcoma Fecha: 2008-09-11 Intervenciones:
|
Completed |
Nombre del estudio: Genetic Biomarkers in Tissue Samples From Patients With Osteosarcoma Condición: Osteosarcoma Fecha: 2013-03-06 Intervenciones: Other: laboratory biomarker analysis Correlative studies |
RECRUITING |
Nombre del estudio: Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study Condición: Locally Advanced Osteosarcoma Fecha: 2024-05-19 Intervenciones: Given IV |
RECRUITING |
Nombre del estudio: Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma Condición: Pulmonary Metastatic Osteosarcoma (pOS) Fecha: 2024-05-19 Intervenciones: Natalizumab is an FDA approved monotherapy for treatment of relapsing forms of MS.It is also indicated for inducing and maintaining clinical |
NOT_YET_RECRUITING |
Nombre del estudio: Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma Condición: Osteosarcoma Fecha: 2024-05-19 Intervenciones: Vactosertib is given twice a day, five days on and two days off in four-week cycles.Vactosertib is a transforming growth factor-beta (TGF-?) typ |